874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy

• Chaitali Dey,
• Srinivas Reddy Boreddy,
• Reshmi Nair,
• Arindam Banerjee,
• Anshu Kuriakose,
• Prashant Kumar Pandey,
• Meena Shri,
• Shruthi Rao,
• Bhadravathi Marigowda Shivakumar,
• Moni Abhram Kuriakose,
• Ram Bhupal Reddy,
• Amritha Suresh,
• Praveen Reddy Moole,
• Usha Bughani,
• Seng-Lai Tan,
• Pradip Nair

Affiliations

Chaitali Dey

Aff393 grid.464755.10000 0004 1768 3485Biocon Research Ltd Bangalore India

Srinivas Reddy Boreddy

1Biofusion Therapeutics Limited, Bangalore, India

Reshmi Nair

1Biofusion Therapeutics Limited, Bangalore, India

Arindam Banerjee

1Biofusion Therapeutics Limited, Bangalore, India

Anshu Kuriakose

1Biofusion Therapeutics Limited, Bangalore, India

Prashant Kumar Pandey

1Biofusion Therapeutics Limited, Bangalore, India

Meena Shri

1Biofusion Therapeutics Limited, Bangalore, India

Shruthi Rao

1Biofusion Therapeutics Limited, Bangalore, India

Bhadravathi Marigowda Shivakumar

1Biofusion Therapeutics Limited, Bangalore, India

Moni Abhram Kuriakose

2Mazumdar Shaw Medical Center, Bangalore, India

Ram Bhupal Reddy

2Mazumdar Shaw Medical Center, Bangalore, India

Amritha Suresh

2Mazumdar Shaw Medical Center, Bangalore, India

Praveen Reddy Moole

3Biocon Biologics Limited, Bangalore, India

Usha Bughani

1Biofusion Therapeutics Limited, Bangalore, India

Seng-Lai Tan

4Bicara Therapeutics Limited, Cambridge, MA, USA

Pradip Nair

1Biofusion Therapeutics Limited, Bangalore, India